Abstract
Background The Holuhraun volcanic eruption September 2014 to February 2015 emitted large amounts of sulfur dioxide (SO2).
Objectives The aim of this study was to determine the association between volcanic SO2 gases on general population respiratory health in the Icelandic capital area some 250 km from the eruption site.
Methods Respiratory health outcomes were: asthma medication dispensing (AMD) from the Icelandic Medicines Register, medical doctor consultations in primary care (PCMD) and hospital emergency department visits (HED) in Reykjavík (population: 215 000) for respiratory disease from 1 January 2010 to 31 December 2014. The associations between daily counts of health events,and daily mean SO2 concentration and high SO2 levels (24-hour mean SO2>125µg/m3) were analyzed using generalized additive models.
Results After the eruption began, AMD was higher than before (129.4 vs. 158.4 individuals per day, p<0.05). Increases in SO2 concentration were associated with an estimated increase in AMD by 1.05% (95% CI 0.48 - 1.62%) per 10 µg/m3 at lag 0-2, 1.51% (95% CI 0.63 – 2.40%) increase in individuals under 18 years of age. PCMD for respiratory causes increased by 1.52% (95% CI 1.04 -2.00%) per 10 µg/m3 SO2 at lag 0-2. For HED, only effect estimated for individuals aged 64 years and older were significantly increased, by 1.541% (95% CI 0.02-3.07%) per 10 µg/m3 SO2 at lag 0-2. Following days with SO2 levels above 125 µg/m3, AMD and PCMD were increased in all age groups, in AMD mostly so in individuals under 18 by 20.4%(95%CI 4.8 – 23.4%), and adult PCMD visits by 24.1%(95%CI 16.8 – 31.3%). HED was significantly increased in elderly by 26.3% (95%CI 5.56-47.0).
Discussion High levels of volcanic SO2 are associated with increases in dispensing of AMD, and health care utilization in primary and tertiary care. Individuals with prevalent respiratory disease may be particularly susceptible.
Funding The study was funded by the Icelandic Ministry of Health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the Icelandic Ministry of Health.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The full health data contains sensitive individual-level information and is not publicly available. The health data can be made available to researchers after approval of a formal application to the Icelandic Directorate of Health and the Icelandic Bioethics committee (reference: VSNb2015050022/03.01). The data from the EAI air quality monitoring stations is publicly available in real-time, and archived data can be obtained from the EAI upon request.
